Clinical Trials/ACTRN12605000009617

ACTRN12605000009617

Active, not recruiting

Phase 3

Multi-centre randomised trial to evaluate the effect of early decompressive craniectomy on neurological function in patients with severe traumatic brain injury

ational Trauma Research Institute, The Alfred0 sites165 target enrollmentJuly 14, 2005

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Not specified
Sponsor: ational Trauma Research Institute, The Alfred
Enrollment: 165
Status: Active, not recruiting
Last Updated: 6 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

July 14, 2005

End Date

TBD

Last Updated

6 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

ational Trauma Research Institute, The Alfred

Eligibility Criteria

Inclusion Criteria

•First 72 hours from time of injury\-Severe diffuse traumatic brain injury\-ICP monitor in\-situ \-Refractory intracranial hypertension

Exclusion Criteria

•Mass lesion\>3cm\-EDH/SDH\>0\.5cm or requiring evacuation\-Spinal cord injury\-Penetrating brain injury\-Cardiac arrest at scene\-Fixed dilated pupils and GCS\=3\-Neurosurgery contraindicated\-No chance of survival after review of CT brain scan and clinical findings (Neurosurgeon decision).

Outcomes

Primary Outcomes

Not specified

Similar Trials

The prophylactic hypothermia trial to lessen traumatic brain injury – randomised controlled trial.Severe traumatic brain injuryNeurological - Other neurological disordersInjuries and Accidents - Other injuries and accidents

ACTRN12609000764235Australian and New Zealand Intensive Care-Research Centre, Monash University500

Active, not recruiting

Trial to evaluate the efficacy of fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in patients with head and neck cancer undergoing radiotherapy.Patients with head and neck cancer .MedDRA version: 21.1Level: PTClassification code 10067821Term: Head and neck cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]

EUCTR2015-005110-30-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI158

Active, not recruiting

A multicenter randomized trial to evaluate the efficacy of tocilizumab in patients with severe Coronavirus Disease 2019 (Covid-19) pneumonia failing glucocorticoids.polmonite severa da coronavirus 2019MedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]

EUCTR2020-005291-35-ITAOU POLICLINICO DI MODENA640

A multicenter randomized trial to evaluate the efficacy of pioglitazone to improve renal outcome in ANCA-associated vasculitis - RENATOANCA-associated vasculitisTherapeutic area: Diseases [C] - Immune System Diseases [C20]

CTIS2022-501057-36-00Assistance Publique Hopitaux De Paris126

Active, not recruiting

A multi-centre randomised study to evaluate the efficacy of Betaferon-interferon-beta-1b (IFNB-1B) 500 mcg therapy in the induction of tolerance to IFNB in MS patients with neutralising antibodies (NAbs) to IFNB-1a (Rebif) - Betaferon NaB Anergy StudyMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system of unknown aetiology. It is the commonest cause of disability in young adults. The prevalence in the UK is approximately 125/100,000 of the population with an annual incidence of 6/100,000. Approximately 80,000 individuals are affected with MS in the UK.

EUCTR2005-005751-18-GBCL Biomedicine R&D Unit100